Batch Fermentation and Microbiome Analysis

Sponsor
Société des Produits Nestlé (SPN) (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06097130
Collaborator
(none)
100
1
12.6
8

Study Details

Study Description

Brief Summary

The correlation between diet and microbiota as well as the effect of microbiota on human health is well established. Studies have shown that people following specific diets have different microbiome profile compared to those following traditional or ordinary diets. In order to screen several food ingredients for their effects on human microbiota composition and metabolic activities, in vitro studies are proposed. Nutrients are added in-vitro in fecal sample, eliminating the need for participants to consume any nutritional product. The batch fermentation in vitro system simulates human colonic microbiota from fecal samples, enabling the complex mixture of microorganisms. This system could serve as a simple model to simulate the diversity as well as the metabolism of human colonic microbiota. We will evaluate the effect on nutrient/s on the age specific microbiome via an in vitro fermentation approach for the 0 to 60 year-old period.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Other
    Time Perspective:
    Other
    Official Title:
    Evaluation of the Effect of Different Nutrients on the Gut Microbiota Composition and Metabolic Activity by Using in Vitro Batch Fermentation and Cellular Models
    Anticipated Study Start Date :
    Jan 15, 2024
    Anticipated Primary Completion Date :
    Jan 31, 2025
    Anticipated Study Completion Date :
    Jan 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Change in microbiota composition [Through study completion, an average of 1 year]

      Measured by 16s rRNA sequencing or next Generation Sequencing (NGS) or by qPCR

    Secondary Outcome Measures

    1. Change in Short Chain Fatty Acids (SCFA) [Through study completion, an average of 1 year]

      Measured using Gas Chromatography (GC)

    2. Change in metabolic profile [Through study completion, an average of 1 year]

      Measured using Gas Chromatography (GC) or Gas chromatography-mass spectrometry (GC-MS)

    3. Protein expression of epithelial cells [Through study completion, an average of 1 year]

      Measured by western blot

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    0 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Healthy participant aged from 0 to 60 (based on medical history, physical examination and review of childhood growth chart)

    • Written informed consent has been obtained from the parent(s)/legally acceptable representative (LAR) of toddlers and teenagers

    • Written informed consent has been obtained for participants aged from 14 years old and above

    • Child's parent(s)/legal representative or participant is willing and able to fulfill the requirements of the study protocol.

    • Ability to collect their or their infant/child's fecal sample.

    Exclusion Criteria:
    • The parent(s)/legally acceptable representative (LAR) is not able to provide evidence of parental authority or legal representation.

    • Participant following a particular regimen of any type such as vegan, vegetarian, ketogenic, paleo diet,

    • Chronic or recurrent diarrhea with spontaneous bowel movements more often than 2 times daily,

    • Antibacterial/antifungal therapy during the 3 months prior to study enrolment,

    • Medications or supplements that are known to alter gut function or microbiota (i.e. acid antisecretory drugs, pre-/probiotics supplements, laxatives) during the 4 weeks prior to study enrolment,

    • Prior gastrointestinal surgery (apart from appendectomy, cholecystectomy or herniotomy),

    • Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer,

    • Artificially sweetened beverage intake higher than 1000 ml/ per day,

    • Current or history of gastrointestinal diseases like (Celiac Disease, Crohn's Disease, Ulcerative colitis, Irritable Bowel Syndrome, infantile colic, recurrent abdominal pain, functional constipation, ulcers, infections (based on anamnesis),

    • Participants participating in another interventional study,

    • Participants/parents having a hierarchical or family link with the research team members.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nestle Clinical Innovation Lab Lausanne Vaud Switzerland 1000

    Sponsors and Collaborators

    • Société des Produits Nestlé (SPN)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Société des Produits Nestlé (SPN)
    ClinicalTrials.gov Identifier:
    NCT06097130
    Other Study ID Numbers:
    • 1920NR
    First Posted:
    Oct 24, 2023
    Last Update Posted:
    Oct 24, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Société des Produits Nestlé (SPN)

    Study Results

    No Results Posted as of Oct 24, 2023